CFM
VIGL

Catalyst Funds Management’s Vigil Neuroscience VIGL Stock Holding History

Catalyst Funds Management’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,100
Closed -$13.9K – 1243
2024
Q3 		$13.9K Hold
4,100
– – ﹤0.01% 1139
2024
Q2 		$16.4K Buy
+4,100
New +$14K ﹤0.01% 747

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Catalyst Funds Management's VIGL Position: Q4 2024 in Review

Catalyst Funds Management sold out of Vigil Neuroscience (VIGL) in Q4 2024, closing a stake of 4,100 shares — an estimated $13.9K sold.

Catalyst Funds Management first reported a position in VIGL in Q2 2024 and held it in 2 quarters. The position peaked at $16.4K in Q2 2024. 51 funds tracked by Wall St. Rank hold VIGL as of Q4 2024.

  • Catalyst Funds Management reported no remaining Vigil Neuroscience position as of Q4 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 4,100 Vigil Neuroscience shares in Q4 2024, an estimated $13.9K.
  • Catalyst Funds Management first reported a position in Vigil Neuroscience in Q2 2024 and held it in 2 quarters.
  • Catalyst Funds Management's Vigil Neuroscience position peaked at $16.4K in Q2 2024.
  • 51 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q4 2024.

Based on Catalyst Funds Management's 13F filing for Q4 2024, filed 10 Feb 2025.